vs

Side-by-side financial comparison of ECARX Holdings Inc. (ECX) and Penumbra Inc (PEN). Click either name above to swap in a different company.

Penumbra Inc is the larger business by last-quarter revenue ($385.4M vs $323.3M, roughly 1.2× ECARX Holdings Inc.). Penumbra Inc runs the higher net margin — 12.3% vs -21.4%, a 33.6% gap on every dollar of revenue. On growth, Penumbra Inc posted the faster year-over-year revenue change (22.1% vs 6.5%). Penumbra Inc produced more free cash flow last quarter ($68.0M vs $-86.5M).

ECARX Holdings Inc. is a global mobility technology provider specializing in integrated smart vehicle solutions, including in-vehicle infotainment systems, advanced driver assistance technologies, and connected car cloud services. It primarily partners with automotive manufacturers across the world, with a strong operational presence in the Chinese and European markets.

Penumbra, Inc. is an American medical device company headquartered in Alameda, California. The company was founded by Arani Bose and Adam Elsesser in 2004. It manufactures devices for interventional therapies to treat vascular conditions such as stroke and aneurysm.

ECX vs PEN — Head-to-Head

Bigger by revenue
PEN
PEN
1.2× larger
PEN
$385.4M
$323.3M
ECX
Growing faster (revenue YoY)
PEN
PEN
+15.6% gap
PEN
22.1%
6.5%
ECX
Higher net margin
PEN
PEN
33.6% more per $
PEN
12.3%
-21.4%
ECX
More free cash flow
PEN
PEN
$154.5M more FCF
PEN
$68.0M
$-86.5M
ECX

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
ECX
ECX
PEN
PEN
Revenue
$323.3M
$385.4M
Net Profit
$-69.1M
$47.3M
Gross Margin
15.5%
68.0%
Operating Margin
-20.2%
15.4%
Net Margin
-21.4%
12.3%
Revenue YoY
6.5%
22.1%
Net Profit YoY
12.8%
40.6%
EPS (diluted)
$-0.20
$1.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ECX
ECX
PEN
PEN
Q4 25
$385.4M
Q3 25
$354.7M
Q2 25
$323.3M
$339.5M
Q1 25
$324.1M
Q4 24
$315.5M
Q3 24
$301.0M
Q2 24
$303.5M
$299.4M
Q1 24
$278.7M
Net Profit
ECX
ECX
PEN
PEN
Q4 25
$47.3M
Q3 25
$45.9M
Q2 25
$-69.1M
$45.3M
Q1 25
$39.2M
Q4 24
$33.7M
Q3 24
$29.5M
Q2 24
$-79.2M
$-60.2M
Q1 24
$11.0M
Gross Margin
ECX
ECX
PEN
PEN
Q4 25
68.0%
Q3 25
67.8%
Q2 25
15.5%
66.0%
Q1 25
66.6%
Q4 24
66.8%
Q3 24
66.5%
Q2 24
22.6%
54.4%
Q1 24
65.0%
Operating Margin
ECX
ECX
PEN
PEN
Q4 25
15.4%
Q3 25
13.8%
Q2 25
-20.2%
12.0%
Q1 25
12.4%
Q4 24
13.6%
Q3 24
11.7%
Q2 24
-22.2%
-27.0%
Q1 24
4.3%
Net Margin
ECX
ECX
PEN
PEN
Q4 25
12.3%
Q3 25
12.9%
Q2 25
-21.4%
13.3%
Q1 25
12.1%
Q4 24
10.7%
Q3 24
9.8%
Q2 24
-26.1%
-20.1%
Q1 24
3.9%
EPS (diluted)
ECX
ECX
PEN
PEN
Q4 25
$1.20
Q3 25
$1.17
Q2 25
$-0.20
$1.15
Q1 25
$1.00
Q4 24
$0.88
Q3 24
$0.75
Q2 24
$-0.23
$-1.55
Q1 24
$0.28

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ECX
ECX
PEN
PEN
Cash + ST InvestmentsLiquidity on hand
$86.2M
$186.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$-293.7M
$1.4B
Total Assets
$494.9M
$1.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ECX
ECX
PEN
PEN
Q4 25
$186.9M
Q3 25
$321.0M
Q2 25
$86.2M
$421.8M
Q1 25
$376.1M
Q4 24
$324.4M
Q3 24
$280.5M
Q2 24
$108.4M
$288.3M
Q1 24
$223.1M
Stockholders' Equity
ECX
ECX
PEN
PEN
Q4 25
$1.4B
Q3 25
$1.4B
Q2 25
$-293.7M
$1.3B
Q1 25
$1.2B
Q4 24
$1.2B
Q3 24
$1.1B
Q2 24
$-198.5M
$1.2B
Q1 24
$1.2B
Total Assets
ECX
ECX
PEN
PEN
Q4 25
$1.8B
Q3 25
$1.7B
Q2 25
$494.9M
$1.7B
Q1 25
$1.6B
Q4 24
$1.5B
Q3 24
$1.5B
Q2 24
$555.0M
$1.5B
Q1 24
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ECX
ECX
PEN
PEN
Operating Cash FlowLast quarter
$-82.0M
$86.5M
Free Cash FlowOCF − Capex
$-86.5M
$68.0M
FCF MarginFCF / Revenue
-26.7%
17.7%
Capex IntensityCapex / Revenue
1.4%
4.8%
Cash ConversionOCF / Net Profit
1.83×
TTM Free Cash FlowTrailing 4 quarters
$174.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ECX
ECX
PEN
PEN
Q4 25
$86.5M
Q3 25
$58.3M
Q2 25
$-82.0M
$44.9M
Q1 25
$49.0M
Q4 24
$51.1M
Q3 24
$56.5M
Q2 24
$-57.1M
$22.6M
Q1 24
$38.3M
Free Cash Flow
ECX
ECX
PEN
PEN
Q4 25
$68.0M
Q3 25
$42.0M
Q2 25
$-86.5M
$29.4M
Q1 25
$35.5M
Q4 24
$45.7M
Q3 24
$51.0M
Q2 24
$-64.9M
$18.1M
Q1 24
$32.5M
FCF Margin
ECX
ECX
PEN
PEN
Q4 25
17.7%
Q3 25
11.8%
Q2 25
-26.7%
8.7%
Q1 25
11.0%
Q4 24
14.5%
Q3 24
16.9%
Q2 24
-21.4%
6.0%
Q1 24
11.7%
Capex Intensity
ECX
ECX
PEN
PEN
Q4 25
4.8%
Q3 25
4.6%
Q2 25
1.4%
4.6%
Q1 25
4.2%
Q4 24
1.7%
Q3 24
1.8%
Q2 24
2.6%
1.5%
Q1 24
2.1%
Cash Conversion
ECX
ECX
PEN
PEN
Q4 25
1.83×
Q3 25
1.27×
Q2 25
0.99×
Q1 25
1.25×
Q4 24
1.52×
Q3 24
1.91×
Q2 24
Q1 24
3.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ECX
ECX

Segment breakdown not available.

PEN
PEN

Thrombectomy$254.7M66%
Other$130.7M34%

Related Comparisons